Inclusion Body Myositis Market, By Treatment (Pharmacological Treatments, Non-Pharmacological Treatments), By Patient Population (Adult, Pediatric), By End User (Hospitals, Clinics), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Million) for the above-mentioned segments.
Market Size in USD
CAGR5.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.5% |
Market Concentration | High |
Major Players | Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., Novartis AG |
The inclusion body myositis market is estimated to be valued at USD 527.5 Mn in 2024 and is expected to reach USD 767.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2031. The increasing prevalence of autoimmune disorders and rising geriatric population globally are expected to propel the market during the forecast period.